|
Re: Good Grief Charlie Brown….
|
2
|
Resverlogix Corp.
|
Jul 16, 2021 12:34PM
|
|
Re: Give us just one or two NR’s - money, partners & timeframe
|
4
|
Resverlogix Corp.
|
Apr 14, 2021 07:08PM
|
|
Re: Gilead's GS-5829 flops in mCRPC
|
4
|
Zenith Epigenetics
|
Jul 19, 2022 11:47PM
|
|
Re: German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal
|
8
|
Zenith Epigenetics
|
Jun 05, 2021 02:01PM
|
|
Re: German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal
|
8
|
Zenith Epigenetics
|
Jun 05, 2021 07:23PM
|
|
Re: Genentech/Roche BET inhibitor toxicity paper
|
4
|
Resverlogix Corp.
|
Apr 19, 2016 09:07PM
|
|
Re: Genentech/Roche BET inhibitor toxicity paper
|
3
|
Resverlogix Corp.
|
Apr 19, 2016 04:57PM
|
|
Re: Gasoline
|
5
|
Zenith Epigenetics
|
Jan 31, 2017 10:52AM
|
|
Re: Funding do the math Koo
|
4
|
Resverlogix Corp.
|
Jun 23, 2017 02:46PM
|
|
Re: Funding
|
5
|
Resverlogix Corp.
|
Jun 23, 2017 02:38PM
|
|
Re: Financials and MD&A on SEDAR
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jan 31, 2017 10:06AM
|
|
Re: Financials
|
6
|
Zenith Epigenetics
|
Oct 28, 2020 11:56AM
|
|
Re: Finance
|
11
|
Resverlogix Corp.
|
Feb 06, 2021 03:30PM
|
|
Re: Fiercemarkets article
|
8
|
Resverlogix Corp.
|
Mar 23, 2021 01:58PM
|
|
Re: Fiercemarkets article
|
2
|
Resverlogix Corp.
|
Mar 23, 2021 07:47PM
|
|
Re: FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm
|
7
|
Zenith Epigenetics
|
Mar 30, 2021 04:28PM
|
|
Re: Explanation of difference between Endcrinology and CVD
|
10
|
Resverlogix Corp.
|
Oct 05, 2015 12:24PM
|
|
Re: Exempt Distribution - 2022-04-14
|
4
|
Resverlogix Corp.
|
Apr 18, 2022 11:38AM
|
|
Re: Exempt Distribution
|
3
|
Zenith Epigenetics
|
Mar 16, 2020 08:06PM
|
|
Re: Exceptionally good news
|
11
|
Resverlogix Corp.
|
Nov 18, 2019 10:45AM
|
